Neogen Corporation Increase (Decrease) in Other Operating Assets and Liabilities, Net
Neogen Corporation (NEOG) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $12.23 million for the 9-month period ending 2024-02-29, per its 10-Q filed 2024-04-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2024-04-09
- Neogen Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2024-02-29 was $2.34M, a 75.49% decline year-over-year.
- Neogen Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2023-11-30 was $3.89M.
- Neogen Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2023-08-31 was $6.01M.
- Neogen Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2023-02-28 was $9.55M.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month |
|---|---|---|---|
| 2024-02-29 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-04-09 | $6.23M derived: sum of 2 quarters · filed 2024-04-09 | $12.23M 10-Q · filed 2024-04-09 |
| 2023-11-30 | $3.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-01-09 | $9.89M 10-Q · filed 2024-01-09 | |
| 2023-08-31 | $6.01M 10-Q · filed 2023-10-10 | ||
| 2023-02-28 | $9.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-04-09 | $9.54M derived: sum of 2 quarters · filed 2024-04-09 | $3.58M 10-Q · filed 2024-04-09 |
| 2022-11-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-01-09 | -$5.97M 10-Q · filed 2024-01-09 | |
| 2022-08-31 | -$5.96M 10-Q · filed 2023-10-10 | ||
| 2011-08-31 | $114.00K 10-Q · filed 2011-09-30 | ||
| 2010-08-31 | $0.00 10-Q · filed 2011-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |